We are a consortium of fourteen partners, aiming to maximize the development and implementation of next-generation influenza vaccine candidate(s) with broader and longer-lasting protection. The project is named “ENDFLU”, acronym for Evaluation of ratioNally Designed inFLUenza vaccines.
The ENDFLU consortium includes key opinion leaders (KOLs) and experts from Europe and India with strong international standing in influenza vaccine development, including both scientific/technical in-depth understanding of the virus and immunological processes, and with access to all preclinical/nonclinical relevant models for efficacy (and safety) testing, and early phase clinical development.